Antimicrobial resistance in Escherichia coli strains from urinary tract infections

Journal of the National Medical Association

Volumn 101, Issue 12, 2009, Pages 1268-1273

  Aboderin, Oladipo A ^a   Abdu, L Rasheed ^b   Odetoyin, Babatunde W ^a   Lamikanra, Adebayo ^a  

^a OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

^b NIGER DELTA UNIVERSITY   (Nigeria)

Author keywords

Bacteria; Nigeria; Urinary tract infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; NALIDIXIC ACID; NITROFURANTOIN; OFLOXACIN; TETRACYCLINE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIURIA; CHILD; CLINICAL ARTICLE; ESCHERICHIA COLI; FEMALE; HUMAN; INFANT; MALE; NIGERIA; NONHUMAN; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; URINALYSIS; URINARY TRACT INFECTION;

EID: 75249085912     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)31138-X     Document Type: Article

References (51)

1. Stamm WE. The epidemiology of urinary tract infections: Risks factors reconsidered. Inter Sci Conf Antimicrob Agents Chemother. 1999;39:769.
2. Karlowsky JA, Kelly LJ, Thornsberry C, et al. Trends in Antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother. 2002;46:2540-2545.
3. Sahm DF, Thornsberry C, Mayfield DC, et al. Multidrug-resistant urinary tract isolates of Escherichia coli: Prevalence and patient demographics in the United States in 2000. Antimicrob Agents Chemother. 2001;45:1402-1406.
4. Manges AR, Tabor H, Tellis P, et al. Endemic and epidemic lineages of Escherichia coli that causes urinary tract infections. Emerg Infect Dis. 2008;14:1575-1583.
5. Gupta K, Sahm DF, Mayfield D, et al. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin lnfect Dis. 2001;33:89-94.
6. Prats G, Navarro F, Mirelis B, et al. Escherichia coli serotype 015:K52:H1 as uropathogenic clone. J Clin Microbiol. 2000;38:201-209.
7. Johnson JR, Stell AL, O'Bryan TT, et al. Global molecular epidemiology of the 015:K52:H1 extraintestinal pathogenic Escherichia coli clonal group: evidence of distribution beyond Europe. J Clin Microbiol. 2002;40:1913-1923.
8. Pitout JD, Gregson DB, Church DL, et al. Community-wide outbreaks of clonally related CTX-M-14 β-lactamase-producing Escherichia coli strains in the Calgary Health Region. J Clin Microbiol. 2005;43:2844-2849.
9. Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America. Clin Infect Dis. 1999;29:745-758.
10. Marcus EL, Altmark L, Shapiro M, et al. Antimicrobial resistance patterns among urine isolates from patients in a geriatric hospital and from older patients in a general hospital. J Am Med Dir Assoc. 2001;2:34-40.
11. Oteo J, Campos J, Baquero F. Antibiotic resistance in 1962 invasive isolates of Escherichia coli in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2001). J Antimicrob Chemother. 2002;50:945-952.
12. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. JAMA. 1999;281:736-738.
13. Karlowsky JA, Hoban DJ, Decorby MR, et al. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Antimicrob Agents Chemother. 2006;50:2251-2254.
14. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA. 2000;283:1583-1590.
15. Brown PD, Freeman A, Foxman B. Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan. Clin Infect Dis. 2002;34:1061-1066.
16. Karlowsky JA, Hoban DJ, Decorby MR, et al. Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study. Anfimicrob Agents Chemother. 2006;50:2251-2254.
17. Hooton TM. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. Int J Antimicrob Agents. 2003;2:65-72.
18. Marijan T, Jasmina Vrane J, Bedeni B, et al. Emergence of Uropathogenic Extended-Spectrum β Lactamases-Producing Escherichia coli Strains in the Community. Coll Antropol. 2007;31:227-233.
19. Suzuki S, Shibata N, Yamane K, et al. Change in the prevalence of extended-spectrumb-lactamase-producing Escherichia coli in Japan by clonal spread. J Antimicrob Chemother. 2009;63,72-79.
20. Cormican M, Morris D, Corrbet-Feeney G, et al. Extended Spectrum β-Lactamase Production and Fluoroquinolone Resistance in Pathogens Associated with Community Acquired Urinary Tract Infection. Diagn Microbiol Infect Dis. 1998;32:317.
21. Colodner R, Keness Y, Chazan B, et al. Antimicrobial susceptibility of community-acquired uropathogens in northern Israel. Int J Antimicrob Agents. 2001:18:189.
22. Brigante G, Luzzaro F, Perilli M. Evolution of CTX-M-type β-lactamases in isolates of Escherichia coli infecting hospital and community patients. Int J Antimicrob Agents. 2005;25:157-162.
23. Lescure FX, Eveillard M, Douadi Y, et al. Community-acquired multiresisfant bacteria: an emerging problem? J Hosp lnfect. 2001;49:149-151.
24. Kim S, Kim J, Kang Y. Occurrence of extended-spectrum b-lactamases in members of the genus Shigella in the Republic of Korea. J Clin Microbiol. 2004;42:5264-5269.
25. Ozden M, Kalkan A, Demirdag K. Ciprofloxacin and co-trimoxazole resistance and extended spectrum β-lactamase production in Escherichia coli strains isolated from urinary tract infections. Int J Antimicrob Agents. 2003;21:492-493.
26. Woodford N, Ward ME, Kaufmann ME, et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum b-lactamases in the UK. J Antimicrob Chemother. 2004;54:735-743.
27. Pitout JDD, Nadmann P, Laupland KB, et al. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother. 2005;56:52-59.
28. Okeke IN, Fayinka ST, Lamikanra A. Antibiotic Resistance in Escherichia coli from Nigerian Students, 1986-1998; Emerg Infect Dis. 2000;6:393-396.
29. Lamikanra A, Ndep RB. Trimethoprim resistance in urinary tract pathogens in two Nigerian hospitals. J Antimicrob Chemother. 1989;23:151-154.
30. Farmer JJ, Davis BR, Hickman-Brenner FW. Biochemical identification of new species and biogroups of Enterobacteriaceae isolated from clinical specimens. J Clin Microbiol. 1985;21:46-76.
31. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Fifteen Informational Supplement. M100-S15,2005:25(1).
32. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Eighteen Informational Supplement M100-S18. Wayne, PA: National Committee for Clinical Laboratory Standards; 2008:28(1).
33. Hima-Lerible H, Ménard D, Talarmin A. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Bangui, Central African Republic. J Antimicrob Chemother. 2003;51:192-194.
34. Randrianirina F, Soares J-L, Carod J-F, et al. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Antananarivo, Madagascar. J. Antimicrob. Chemother. 2007;59:309-312.
35. Kose Y, Abasiyanik MF, Salih BA. Antibiotic resistance of Escherichia coli urinary tract isolates in Riza province, Turkey. J lnfect Developing Countries. 2007;1:147-150.
36. Kariuki S, Revathi G, Corkill J, Kiiru J, Mwituria N, Hart CA. Escherichia coli from community-acquired urinary tract infections resistant to fluaoquinolones and extended-spectrum beta-lactams. J Infect Developing Countries. 2007;1:257-262.
37. Tenva FC, Hughes JM. The challenges of emerging infectious diseases: development and spread of multiply-resistant bacterial pathogens. JAMA. 1996;275:300-304.
38. Ahmed AA, Osman H, Mansour AM et al. Antimicrobial agent resistance in bacterial isolates from patients with diarrhea and urinary tract infection in Sudan. Am J Trop Med Hyg. 2000;63:259-263.
39. Sire J-M, Nabeth P, Perrier-Gros-Claude J-D, et al. Antimicrobial resistance in outpatient Escherichia coli urinary isolates in Dakar, Senegal. J infect Developing Countries. 2007;1:263-268.
40. Sotto A, De Boever CM, Fabbro-Peray P, et al. Risk Factors for Antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study. J Clin Microbiol. 2001;39:438-444.
41. Okeke, IN, Lamikanra A, Edelman R. Socioeconomic and behavioural factors leading to acquired bacterial resistance to antibiotics in developing countries. Emerg Infect Dis. 1999;5:1-12.
42. Arredondo-Garcia JL, Amabile-Cuevas CF. High resistance prevalence towards ampicillin, co-trimoxazole and ciprofloxacin, among uropathogenic Escherichia coli isolates in Mexico City. J Infect Developing Countries. 2008;2:350-353.
43. Manges AR, Natarajan P, Solberg OD, et al. The changing prevalence of drug-resistant Escherichia coli clonal groups in a community: evidence for community outbreaks of urinary tract infections. Epidemiol Infect. 2006;134:425-431.
44. Babalola OO, Lamikanra A. Pattern of antibiotic purchases in community pharmacies in South Western Nigeria. Journal of Social and Administra tive Pharmacy. 2002;19:33-38.
45. Davidson RJ, Davis I, Willey BM, et al. Antimalarial therapy selection for quinolone resistance among Escherichia coli in the absence of quinolone exposure, in tropical South America. PLoS ONE. 2008;3:e2727.
46. Johnson JR. Antimicrobial drug-resistant Escherichia coli from humans and poultry products, Minnesota and Wisconsin, 2002-2004. Emerg Infect Dis. 13:838-846.
47. Johnson JR, Kuskowski MA, Gajewski A, et al. Virulence characteristics and phylogenetic background of multidrug-resistant and antimicrobial-susceptible clinical isolates of Escherichia coli from across the United States, 2000-2001. J Infect Dis. 2004;190:1739-1744.
48. Johnson JR, Murray AC, Gajewski A, et al. Isolation and molecular characterization of nalidixic acid-resistant extraintestinal pathogenic Escherichia coli from retail chicken products, Antimicrob Agents Chemother. 2003;47:2161-2168.
49. Sabate M, Prats G, Moreno E, et al. Virulence and antimicrobial resistance profiles among Escherichia coli strains isolated from human and animal wastewater products. Res. Microbiol. 2008;159:288-293.
50. Odetoyin WB, Aboderin AO, Ikem RT, Kolawole BA, Oyelese AO. Asymptomatic bacteriuria in patients with diabetes mellitus in Ile-Ife, South-West, Nigeria. East Afr Med J. 2008;85:18-23.
51. Urassa W, Lyamuya E, Mhalu F. Recent trends on bacterial resistance to antibiotics. East Afr Med J. 1997;74:129-133.